Global Lung Cancer Therapeutics Market
According to the report " Lung Cancer Therapeutics Market ", published by Market Data Forecast , the global market is projected to reach USD 7.81 Billion by 2021 , at a CAGR of 6.7 % from 2016 to 2021 .
Lung cancer is a malignant lung carcinoma which is characterized by irregular cell growth in lung tissue . As the tumour grows in size , it reduces the lungs ’ ability to provide oxygen to arteries , veins and capillaries . It is the common cause of mortality and illness not only in developed countries but also in developing countries . Smoking is thought as a main cause of lung cancer , though lung cancer also follows in non-smokers .
Air pollution , amplified alcohol consumption , varying life style , smoking , unhealthy food , and no physical activity are the factors indirectly driving the market . Governments in the developing economies are providing awareness among the people about the cancer . As the geriatric population is likely to increase , the incidence of lung cancer is predicted to rise , thus acting as a driver for revenue growth .
Global Market for Lung Cancer Therapeutics is segmented based on Type of Treatment and Region into further sub-segments as follows :
1 . By Treatment Type : �
�
�
Chemotherapy
• Cisplatin
• Taxol
• Navelbine
• Camptosar
• Alimta
Radiotherapy
• External Beam
• Internal Beam
• Systemic
Drugs Type
• Abraxane
• Avastin
• Crizotinib
• Docetaxel
• Gefitinib
2 . By Geography :
� � � � �
North America Europe Asia-Pacific Latin America Middle-East and Africa
+ 1 888-702-9626 | www . marketdataforecast . com | contact @ marketdataforecast . com